PMID- 10700602
OWN - NLM
STAT- MEDLINE
DCOM- 20000425
LR  - 20221207
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 858
IP  - 1
DP  - 2000 Mar 6
TI  - Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on 
      the morphology of serotonergic nerve terminals using serotonin 
      immunohistochemistry.
PG  - 92-105
AB  - We compared the effects of treatment with high doses of fluoxetine, sibutramine, 
      sertraline, and dexfenfluramine for 4 days on brain serotonergic nerve terminals 
      in rats. Methylenedioxymethamphetamine (MDMA) and 5,7-dihydroxytryptamine 
      (5,7-DHT) were used as positive controls because both compounds deplete brain 
      serotonin. Food intake and body weight changes were also monitored and yoked, 
      pair-fed animals were used to control for possible changes in morphology due to 
      nutritional deficits. Fluoxetine, sibutramine, sertraline and dexfenfluramine all 
      produced a significant reduction in body weight. Fluoxetine, sibutramine and 
      sertraline treatment resulted in no depletion of brain serotonin but produced 
      morphological abnormalities in the serotonergic immunoreactive nerve network. In 
      contrast, dexfenfluramine and MDMA depleted brain serotonin and produced 
      morphological changes in the serotonin nerve network. These results indicate that 
      even though fluoxetine, sibutramine and sertraline do not deplete brain 
      serotonin, they do produce morphological changes in several brain regions (as 
      identified by serotonin immunohistochemistry). Dexfenfluramine and MDMA, on the 
      other hand, markedly deplete brain serotonin and also produce morphological 
      changes. Collectively, these results lend support to the concept that all 
      compounds acting on brain serotonin systems, whether capable of producing 
      serotonin depletion or not, could produce similar effects on the morphology of 
      cerebral serotonin systems.
FAU - Kalia, M
AU  - Kalia M
AD  - Department of Biochemistry, Molecular Pharmacology and Anesthesiology, Jefferson 
      Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. 
      mkalia@msn.com
FAU - O'Callaghan, J P
AU  - O'Callaghan JP
FAU - Miller, D B
AU  - Miller DB
FAU - Kramer, M
AU  - Kramer M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Appetite Depressants)
RN  - 0 (Cyclobutanes)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 333DO1RDJY (Serotonin)
RN  - E35R3G56OV (Dexfenfluramine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - QUC7NX6WMB (Sertraline)
RN  - WV5EC51866 (sibutramine)
SB  - IM
MH  - Animals
MH  - Appetite Depressants/pharmacology
MH  - Body Weight/drug effects
MH  - Cyclobutanes/pharmacology
MH  - Dexfenfluramine/pharmacology
MH  - Eating/drug effects
MH  - Fluoxetine/pharmacology
MH  - Immunohistochemistry
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/pharmacology
MH  - Prefrontal Cortex/drug effects/metabolism/pathology
MH  - Presynaptic Terminals/*drug effects/*ultrastructure
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/*metabolism
MH  - Serotonin Agents/*pharmacology
MH  - Serotonin Receptor Agonists/pharmacology
MH  - Selective Serotonin Reuptake Inhibitors/pharmacology
MH  - Sertraline/pharmacology
EDAT- 2000/03/04 09:00
MHDA- 2000/04/29 09:00
CRDT- 2000/03/04 09:00
PHST- 2000/03/04 09:00 [pubmed]
PHST- 2000/04/29 09:00 [medline]
PHST- 2000/03/04 09:00 [entrez]
AID - S0006-8993(99)02430-0 [pii]
AID - 10.1016/s0006-8993(99)02430-0 [doi]
PST - ppublish
SO  - Brain Res. 2000 Mar 6;858(1):92-105. doi: 10.1016/s0006-8993(99)02430-0.